MedPath

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Phase 3
Conditions
Alzheimer's Disease Psychosis
Interventions
Registration Number
NCT06194799
Lead Sponsor
ACADIA Pharmaceuticals Inc.
Brief Summary

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
752
Inclusion Criteria
  • Subject has successfully completed ACP-204-006 study
  • Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential
  • Subject has a designated study partner/caregiver
  • Subjects are able to complete all study visits with a study partner/caregiver
  • Signed inform consent form with a caregiver or legal representative
Exclusion Criteria
  • Requires treatment with a medication prohibited by the protocol
  • Is in hospice and receiving end-of-life palliative care, or has become bedridden
  • Female who is pregnant or breastfeeding
  • Unstable clinically significant medical condition other than AD
  • Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study

Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ACP-204ACP-204ACP-204 30mg or 60mg
Primary Outcome Measures
NameTimeMethod
Treatment-emergent adverse events52 Weeks

Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) over 52 weeks of treatment. The Safety population consists of all subjects who received at least one dose of study drug in this study.

Secondary Outcome Measures
NameTimeMethod
Clinical Global Impression-Improvement in the ADP context (CGI-I-ADP) score52 Weeks

Trial Locations

Locations (46)

Jovanovic University Clinical Centre of Kragujevac

🇷🇸

Kragujevac, Serbia

University Clinical Center Nis

🇷🇸

Niš, Serbia

Hospital Universitario Virgen Macarena

🇪🇸

Sevilla, Spain

ATP Clinical Research

🇺🇸

Costa Mesa, California, United States

National Institute Of Clinical Research

🇺🇸

Garden Grove, California, United States

New Life Medical Research Center

🇺🇸

Hialeah, Florida, United States

Reliable Clinical Research LLC

🇺🇸

Hialeah, Florida, United States

Homestead Associates in Research Inc.

🇺🇸

Miami, Florida, United States

Premier Clinical Research Institute Inc

🇺🇸

Miami, Florida, United States

Advanced Clinical Research

🇺🇸

Miami, Florida, United States

Scroll for more (36 remaining)
Jovanovic University Clinical Centre of Kragujevac
🇷🇸Kragujevac, Serbia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.